Physician profile
Mandy Thompson
NPI 1194749101
$1,673.71
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $199 · 2020: $1,009 · 2021: $466.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $227.04 | 2019-2021 | |
| Abbvie INC. | $195.29 | 2020-2021 | |
| Allergan, INC. | $182.70 | 2020 | |
| Glaxosmithkline, LLC. | $149.11 | 2019-2021 | |
| Eisai INC. | $135.84 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $95.55 | 2020 | |
| Amgen INC. | $80.31 | 2019-2021 | |
| Esperion Therapeutics, INC. | $71.77 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $69.45 | 2019-2021 | |
| Novo Nordisk INC | $61.96 | 2020 | |
| Amarin Pharma, INC. | $52.47 | 2020-2021 | |
| Clarus Therapeutics INC. | $51.17 | 2021 | |
| Aytu Biopharma, INC. | $40.07 | 2019-2020 | |
| Antares Pharma, INC. | $35.04 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.97 | 2019-2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $24.74 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $23.87 | 2019-2020 | |
| Tersera Therapeutics LLC | $21.40 | 2019 | |
| Ermi LLC | $20.72 | 2020 | |
| Ge Healthcare | $15.41 | 2020 | |
| Biohaven Pharmaceuticals, INC. | $15.35 | 2021 | |
| Boston Scientific Corporation | $14.81 | 2019 | |
| Shire North American Group INC | $13.63 | 2019 | |
| Endo Pharmaceuticals INC. | $13.44 | 2020 | |
| Lilly USA, LLC | $13.10 | 2020 | |
| Currax Pharmaceuticals LLC | $12.91 | 2020 | |
| Genentech USA, INC. | $11.59 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mandy Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.